Endomag Strengthens Board with Key Appointment
Endomag has announced the appointment of Peter Keen as non-executive director, effective immediately.
Since the launch of Magseed®, Endomag’s breast lesion localisation device, in November 2016, interest has exceed expectations. Over 150 hospitals, including 30 of the top 50 ranked cancer centres in the US, are now due to evaluate the technology in the first half of 2017. To build on this success, Mr Keen will focus on supporting the company as it further extends its international reach.
A chartered accountant, Mr Keen has over 30 years’ experience in the management and financing of life science businesses. He founded the technology investment firm Cambridge Innovation Capital and has served on the board of many private and public companies. He is currently a director of both MRC Technology Limited and the Biotechnology Growth Trust plc, a £280m investment trust investing in global biotechnology. For nine years he was the senior independent director of Abcam plc and was a co-founder of Chiroscience Group plc, where he led the £102m initial public offering. Mr Keen was co-founder of the venture capital firm Merlin Biosciences, and as UK Managing Director, was responsible for many early stage healthcare investments. More recently he was a venture partner with the technology VC DFJ Esprit.
Dr. Eric Mayes, CEO of Endomag, said: “On behalf of the Board of Directors, I welcome Peter Keen to his position of non-executive director. His track record, network and experience will be invaluable as we continue the global development of the Company.”
Mr Peter Keen, non-executive director at Endomag, said: “Endomag has made significant progress and the Company’s revenue growth to date has been highly impressive, and the demand for Magseed continues to exceed expectations. I am pleased to take the position at this exciting time and look forward to working with the management team to execute on their vision for the business.”
This article has been republished from materials provided by Endomag. Note: material may have been edited for length and content. For further information, please contact the cited source.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Changing microRNA's Presence in Glioblastoma Cells Could Change the Tumor's SubtypeNews
BWH researchers examined a specific microRNA, miR-128, to help identify glioblastoma subtypes and to determine if altering the microRNA's presence in glioblastoma cells could change the tumor's subtype.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Techniques for Mammary Gland Research
Mar 05 - Mar 09, 2018